Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity … (NCT04927949) | Clinical Trial Compass
CompletedPhase 4
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
France128 participantsStarted 2021-06-08
Plain-language summary
This study aims to evaluate the impact on myocardial reperfusion and residual thrombotic burden of adding Cangrelor -a potent and immediate P2Y12 inhibitor- to ticagrelor in primary PCI patients with high on ticagrelor platelet reactivity compared to standard of care with ticagrelor alone.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* patient admitted for STEMI within 24 hours from symptom onset
* pretreated with ticagrelor, aspirin and enoxaparin (according local protocol)
* successfully treated by primary PCI of a native coronary culprit lesion
* anatomy accessible to optical coherence tomography (OCT or OFDI)
Exclusion Criteria:
* cardiogenic shock
* stent restenosis or thrombosis
* use of glycoprotein IIb/IIIa inhibitors before or during PCI
* known coagulation disease
* high bleeding risk (thrombocytopenia \<100,000/dL, surgery \<30 days, active bleeding)
* uncontrolled arterial hypertension (\>180/110 mmHg)
* history of stroke (ischemic or hemorrhagic) or transient ischemic attack
* known severe renal insufficiency (eGFR \<30 ml/min)
* oral anticoagulation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial looked at 'myocardial blush grade' as its main measure — can you explain what that tells us about how well blood flow was restored to my heart muscle after a stent procedure, and why that matters for my recovery?
2The trial specifically enrolled STEMI patients who had high platelet reactivity and tested whether cangrelor improved reperfusion — based on the completed results, did patients with high platelet reactivity like mine actually show better blood flow outcomes with cangrelor compared to standard treatment?
3Since this is a Phase 4 trial that has already completed, what does the data suggest about the safety profile of cangrelor used during a primary PCI procedure, and are there any side effects I should be aware of if my doctor is considering it for me?
4Cangrelor is given intravenously during the procedure rather than as a pill — how does that affect how it would fit into my care during an emergency heart attack situation, and is it something my hospital already has available?
5Given that this trial has finished and focused on a very specific group — STEMI patients with high platelet reactivity — how would my doctor determine whether my platelet reactivity level is high enough that this approach might be relevant to my treatment plan?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.